Outcome of the Board Meeting
COHANCE · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 5.3 pts less than Nifty Smallcap 250 and 5.0 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Cohance Lifesciences Limited (formerly Suven Pharmaceuticals) has released its audited financial results for Q4 and full year ended March 31, 2026. On a standalone basis, revenue declined to ₹2,030.50 Cr from ₹2,504.43 Cr in the previous year, while net profit fell to ₹228.71 Cr from ₹491.18 Cr. Consolidated revenue stood at ₹2,268.55 Cr versus ₹2,608.50 Cr, with consolidated net profit at ₹150.12 Cr compared to ₹484.24 Cr. The significant declines are partly attributable to the merger with erstwhile Cohance Lifesciences Limited (approved by NCLT in March 2025, effective May 2025), with prior period figures restated. The auditors issued an unmodified opinion with an emphasis of matter on the merger accounting. Exceptional items totaling ₹29.47 Cr include a ₹16.51 Cr customer settlement claim, restructuring costs, and labor code implementation expenses.
The company has experienced substantial declines in both revenue and profitability, largely due to the merger-related costs and a ₹16.51 Cr one-time customer settlement. However, the clean audit opinion and completed merger may provide stability going forward.